https://orcid.org/0000-0001-5599-9593
References
- Bialer M. Clinical pharmacology of valpromide. Clin Pharmacokinet. 1991;20(2):114–122.
- Payen C, Frantz P, Martin O, et al. Delayed toxicity following acute ingestion of valpromide. Hum Exp Toxicol. 2004;23(3):145–148.
- Spiller HA, Krenzelok EP, Klein-Schwartz W, et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. J Toxicol Clin Toxicol. 2000;38(7):755–760.
- Delhumau S, Le Roux G, Meyer G, et al. Surdosage en valpromide: comment interpréter le dosage plasmatique de l’acide valproïque? Toxicol Anal Clin. 2018;30(3):172.
- Blotnik S, Bergman F, Bialer M. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. Drug Metab Dispos. 1996;24(5):560–564.
- Kerr BM, Rettie AE, Eddy AC, et al. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther. 1989;46(1):82–93.
- Bevalot F, Guinet T, Bottinelli C, et al. Limites du dosage de l’acide valproïque dans les intoxications au valpromide. Toxac. 2015;27(2):S35–S6.